Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children

Pediatric Infectious Disease Journal

Volumn 25, Issue 6, 2006, Pages 538-543

  Crommentuyn, Kristel M L ^a   Scherpbier, Henriëtte J ^b   Kuijpers, Taco W ^b   Mathôt, Ron A A ^c   Huitema, Alwin D R ^a   Beijnen, Jos H ^a,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

HIV 1; M8; Nelfinavir; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; LAMIVUDINE; M 8; NELFINAVIR; STAVUDINE; VIRUS RNA;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; COVARIANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; POPULATION MODEL; POPULATION RESEARCH; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT RESPONSE; VALIDATION STUDY;

EID: 33745006594     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000215242.70300.95     Document Type: Article

References (33)

1. King JR, Kimberlin DW, Aldrovandi GM, et al. Antiretroviral pharmacokinetics in the paediatric population: A review. Clin Pharmacokinet. 2002;41:1115-1133.
2. van Rossum AMC, Fraaij PLA, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002;2:93-102.
3. Funk MB, Linde R, Wintergerst U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS. 1999;13:1653-1658.
4. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999;341:1874-1881.
5. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: Week 24 results of a randomized controlled trial-PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses. 2000;16:1113-1121.
6. van Rossum AMC, Geelen SP, Hartwig NG, et al. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34:1008-1016.
7. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis. 1999;28:1109-1118.
8. Bardsley-Elliot A, Plosker GL. Nelfinavir: An update on its use in HIV infection. Drugs. 2000;59:581-620.
9. van Heeswijk RPG, Scherpbier HJ, de Koning LA, et al. The pharmacokinetics of nelfinavir in HIV-1-infected children. Ther Drug Monit. 2002;24:487-491.
10. Rongkavilit C, van Heeswijk RPG, Limpongsanurak S, et al. Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates. J Acquir Immune Defic Syndr. 2002;29:455-463.
11. Schuster T, Linde R, Wintergerst U, et al. Nelfinavir pharmacokinetics in HIV-infected children: A comparison of twice daily and three times daily dosing. AIDS. 2000;14:1466-1468.
12. Capparelli EV, Sullivan JL, Mofenson L, et al. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr Infect Dis J. 2001;20:746-751.
13. Bergshoeff AS, Fraaij PLA, van Rossum AMC, et al. Pharmacokinetics of nelfinavir in children: Influencing factors and dose implications. Antivir Ther. 2003;8:215-222.
14. Gatti G, Castelli-Gattinara G, Cruciani M, et al. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin Infect Dis. 2003;36:1476-1482.
15. Floren LC, Wiznia A, Hayashi S, et al. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics. 2003;112:e220-e227.
16. Hsyu PH, Capparelli EV, Amantea M, Petersen A, Kerr BM. Population pharmacokinetics of nelfinavir and correlation to efficacy in pediatric patients. In: 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8-11, 2001. Abstract 348.
17. Litalien C, Faye A, Compagnucci A, et al. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 2003;22:48-55.
18. Crommentuyn KML, Rosing H, Nan-Offeringa LGAH, Hillebrand MJX, Huitema ADR, Beijnen JH. Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom. 2003;38:157-166.
19. Beal S, Sheiner LB. NONMEM User's Guides. NONMEM Project Group, University of California at San Francisco, 1998.
20. Hu TM, Hayton WL. Allometric scaling of xenobiotic clearance: Uncertainty versus universality. AAPS PharmSci. 2001;3:E29.
21. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30:329-332.
22. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet. 1997;33:313-327.
23. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735-750.
24. Burger DM, Bergshoef AS, de Groot R, et al. Maintaining the nelfinavir trough concentration above 0.8 mg/l significantly improves virological response in HIV-1-infected children. In: 5th International workshop on clinical pharmacology in HIV therapy, Rome, Italy, April 1-3, 2004. Abstract 3.3
25. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59:19-29.
26. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: Pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS. 2002;16:1331-1340.
27. Viracept [Roche web site: package insert]. February 3, 2003. Available at: http://www.roche.nl/producten/spc/vir250tab.pdf. Accessed April 4, 2004.
28. Antal EJ, Grasela TH Jr, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly. Clin Pharmacol Ther. 1989;46:552-559.
29. Mu S, Ludden IM. Estimation of population pharmacokinetic parameters in the presence of non-compliance. J Pharmacokinet Pharmacodyn. 2003;30:53-81.
30. Girard P, Sheiner LB, Kastrissios H, Blaschke TF. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm. 1996;24:265-282.
31. Reddington C, Cohen J, Baldillo A, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2000;19:1148-1153.
32. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109:e61.
33. van Rossum AMC, Bergshoeff AS, Fraaij PLA, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:743-747.